D. Page

Oncology · with Connell · 2015–2016

A researcher in the Science corpus: 2 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom D. Page trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. C. Robert
  2. Antoni Ribas
  3. D. Pardoll
  4. J. Wolchok

Papers from D. Page's perspective

Ordered by how strongly the researchers D. Page trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
  2. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
  3. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma (New England Journal of Medicine)
  4. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients (Nature)
  5. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
  6. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (New England Journal of Medicine)
  7. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer (New England Journal of Medicine)
  8. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (New England Journal of Medicine)
  9. Cancer immunoediting: from immunosurveillance to tumor escape (Nature Immunology)
  10. Pembrolizumab for the treatment of non-small-cell lung cancer. (New England Journal of Medicine)

Their papers